Drug Profile
GCS 100
Alternative Names: GBC-590; GCS-100; GCS-100LE; LJPC-101; NCCGLatest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator Barbara Ann Karmanos Cancer Institute; Wayne State University
- Developer GlycoGenesys; La Jolla Pharmaceutical Company; Prospect Therapeutics
- Class Antineoplastics; Polysaccharides
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell adhesion molecule inhibitors; Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Liver disorders; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal failure
Most Recent Events
- 22 Aug 2022 La Jolla Pharmaceutical Company has been acquired by Innoviva
- 01 Jun 2016 La Jolla Pharmaceutical completes the phase II GCS-100-CS-4003 extension trial for Renal failure (chronic kidney disease) in USA (NCT02155673)
- 08 May 2015 GCS 100 is available for licensing as of 08 May 2015. www.ljpc.com